ArticleDiscover oncology2025
CircRNA CeRNA networks in gastric cancer highlight FAP/FNDC1 as potential prognostic and therapeutic targets.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCircular RNAs (circRNAs) are endogenous non-coding RNAs implicated in the initiation and progression of cancer. The circRNA-miRNA-mRNA competitive endogenous RNA (ceRNA) network exerts a crucial influence on tumor prognosis and therapy. This research aimed to identify novel circRNA-driven ceRNA networks and potential prognostic/therapeutic targets for gastric cancer (GC).
methodsGastric cancer-related circRNA, miRNA, and mRNA datasets were retrieved from the GEO database, accompanied by clinical and expression data from TCGA. Differential expression analysis, ceRNA network construction (Cytoscape_v3.8.0), KEGG/GO enrichment analysis, and survival analyses were conducted using R software.
resultsKEGG analysis of mRNAs within the ceRNA network indicated enrichment in the IL-17 signaling pathway, TNF signaling pathway, and other pathways associated with GC prognosis. Two key ceRNA axes associated with GC prognosis were identified: (1) hsa_circ_0055521/hsa-miR-204-5p/FAP and (2) (hsa_circ_0005051, hsa_circ_0007613, hsa_circ_0045602, hsa_circ_0034398, hsa_circ_0006089)/hsa-miR-32-3p/FNDC1. Survival analysis and immunohistochemical validation (HPA database) verified that FAP and FNDC1 are potential prognostic biomarkers and therapeutic targets for GC.
conclusionThis study identifies three key pathways, two novel prognostic ceRNA networks, six prognosis-related circRNAs, and two target genes (FAP/FNDC1) for GC, offering new directions for GC therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.